Amgen Inc.
Company & revenue
About Amgen Inc.
Who they are
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products.
Detailed revenue, brand and relationship research has not yet been completed for AMGN.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
39
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
60
Fair
Financial Strength
72
Business Quality / Moat
37
Management
85
Growth Quality
32
Risk / Durability
71
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
60
Fully Valued
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
58/100
Building Historical Record
Model Score 58/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently sees meaningful weaknesses in the company-strength profile.
At today’s price, the WSS valuation framework currently reads as moderate rather than unusually attractive.
The model outlook is currently moderate.
No strong positive signal is being highlighted from the currently available summary data.
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for AMGN
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can AMGN maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is AMGN's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is AMGN's debt load manageable relative to cash generation, interest costs and upcoming maturities?
Essential Investment Snapshot
Wall Street Score
39
Opportunity Score
60
Market Cap
$217.52B
P/E Ratio
26.0
EPS
$16.22
52-Week High
$447.03
52-Week Low
$261.43
Beta
0.43
Intrinsic Value
$519.24
Analyst Target
$400.00
Shares Outstanding
542.0M
Total Revenue
$38.13B
Total Debt
$57.30B
Dividend Yield
2.50%
Liquidation Value / Share
$21.56
Annual Dividend
$10.08
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Normal movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for AMGN
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Community Sentiment
0 active · 0 total callsNo personal call yet on AMGN.
What the Bulls Say
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Product opportunity: Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products.
- +Positive free cash flow may provide capacity to invest in growth.
What the Bears Say
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Drug Manufacturers - General industry.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
41
Sep 8, 2026
Change
-2.1
points
Current Score
39
Oct 1, 2026
Category Changes
AMGN decreased 2.1 points because Valuation declined by 9.6 points.
Negative Contributors
- − Valuation declined by 9.6 points
Projected Score
Projected Score
49
Projected Change
+10.0%
Preliminary comparable-period financial changes suggest improvement of approximately 10.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$403.04
Intrinsic Value
$519.24
Difference
−$116.20
-22.4% vs IV
Margin of Safety
22.4%
Related Companies
Drug Manufacturers - GeneralNews
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
Amgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors
Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead
Take the Zacks Approach to Beat the Markets: Bloom Energy, Microsoft & Amgen in Focus
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial